Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Gastrointestinal Neoplasms 3Stomach Neoplasms 2Neoplasms 2Esophageal Neoplasms 2Urinary Bladder Neoplasms 1Sarcoma 1Prostatic Neoplasms 1Pituitary Neoplasms 1Peritoneal Neoplasms 1Pelvic Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Carcinoma, Renal Cell 1Appendiceal Neoplasms 1

Interventions

Carboplatin 156Paclitaxel 154Bevacizumab 96Cyclophosphamide 61Gemcitabine 46olaparib 45Cisplatin 45Topotecan 44niraparib 40liposomal doxorubicin 40pembrolizumab 38Surveys and Questionnaires 33Filgrastim 31Hyperthermic Intraperitoneal Chemotherapy 29Docetaxel 27Taxes 25Blood Specimen Collection 24fludarabine 23Drug Therapy 23Cytoreduction Surgical Procedures 23Peripheral Blood Stem Cell Transplantation 21Etoposide 21Doxorubicin 21Magnetic Resonance Spectroscopy 20durvalumab 17Specimen Handling 17Albumin-Bound Paclitaxel 17Immunoglobulin G 15Disulfides 15Letrozole 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Ovarian Neoplasms × Pafolacianine × Clear all
NCT04941378 2022-06-27

OTL38 Injection (OTL38) for Intra-Operative Imaging of Folate Receptor Positive Ovarian Cancer

Abramson Cancer Center at Penn Medicine

Phase 1 Withdrawn
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡